Literature DB >> 29959199

Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells.

Zhong Chen1, Carter Van Waes1, Xin Xin Quan2, Nga Voong Hawk3, Weiping Chen4, Jamie Coupar2, Steven K Lee2, David W Petersen5, Paul S Meltzer5, Andrew Montemarano6, Martin Braun7.   

Abstract

Cancer stem-like cells are hypothesized to be the major tumor-initiating cell population of human cutaneous squamous cell carcinoma (cSCC), but the landscape of molecular alterations underpinning their signaling and cellular phenotypes as drug targets remains undefined. In this study, we developed an experimental pipeline to isolate a highly enriched CD133+CD31-CD45-CD61-CD24- (CD133+) cell population from primary cSCC specimens by flow cytometry. The CD133+ cells show enhanced stem-like phenotypes, which were verified by spheroid and colony formation in vitro and tumor generation in vivo Gene expression profiling of CD133+/- cells was compared and validated, and differentially expressed gene signatures and top pathways were identified. CD133+ cells expressed a repertoire of stemness and cancer-related genes, including NOTCH and NOTCH1-mediated NF-κB pathway signaling. Other cancer-related genes from WNT, growth factor receptors, PI3K/mTOR, STAT pathways, and chromatin modifiers were also identified. Pharmacologic and genetic targeting of NOTCH1, IKKα, RELA, and RELB modulated NF-κB transactivation, the CD133+ population, and cellular and stemness phenotypes. Immunofluorescent staining confirmed colocalization of CD133+ and IKKα expression in SCC tumor specimens. Our functional, genetic, and pharmacologic studies uncovered a novel linkage between NOTCH1, IKKα, and NF-κB pathway activation in maintaining the CD133+ stem SCC phenotypes. Studies investigating markers of activation and modulators of NOTCH, IKK/NF-κB, and other pathways regulating these cancer stem gene signatures could further accelerate the development of effective therapeutic strategies to treat cSCC recurrence and metastasis. Mol Cancer Ther; 17(9); 2034-48. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29959199      PMCID: PMC6461743          DOI: 10.1158/1535-7163.MCT-17-0421

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  50 in total

1.  "Stemness": transcriptional profiling of embryonic and adult stem cells.

Authors:  Miguel Ramalho-Santos; Soonsang Yoon; Yumi Matsuzaki; Richard C Mulligan; Douglas A Melton
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

2.  A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.

Authors:  Qunzhou Zhang; Shihong Shi; Yun Yen; Jimmy Brown; Joseph Quoc Ta; Anh D Le
Journal:  Cancer Lett       Date:  2009-09-11       Impact factor: 8.679

3.  Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.

Authors:  Wolf-K Hofmann; Sven de Vos; Martina Komor; Dieter Hoelzer; William Wachsman; H Phillip Koeffler
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

4.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Authors:  Suresh Mohan; Robert Vander Broek; Sujay Shah; Danielle F Eytan; Matthew L Pierce; Sophie G Carlson; Jamie F Coupar; Jialing Zhang; Hui Cheng; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

5.  DeltaNp63alpha repression of the Notch1 gene supports the proliferative capacity of normal human keratinocytes and cervical cancer cells.

Authors:  Takashi Yugawa; Mako Narisawa-Saito; Yuki Yoshimatsu; Kei Haga; Shin-ichi Ohno; Nagayasu Egawa; Masatoshi Fujita; Tohru Kiyono
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

Review 6.  Stem cell dynamics in homeostasis and cancer of the intestine.

Authors:  Louis Vermeulen; Hugo J Snippert
Journal:  Nat Rev Cancer       Date:  2014-06-12       Impact factor: 60.716

7.  Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.

Authors:  D C Duffey; Z Chen; G Dong; F G Ondrey; J S Wolf; K Brown; U Siebenlist; C Van Waes
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

8.  Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells.

Authors:  L L Song; Y Peng; J Yun; P Rizzo; V Chaturvedi; S Weijzen; W M Kast; P J B Stone; L Santos; A Loredo; U Lendahl; G Sonenshein; B Osborne; J-Z Qin; A Pannuti; B J Nickoloff; L Miele
Journal:  Oncogene       Date:  2008-06-16       Impact factor: 9.867

9.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

10.  Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer.

Authors:  L K Nottingham; C H Yan; X Yang; H Si; J Coupar; Y Bian; T-F Cheng; C Allen; P Arun; D Gius; L Dang; C Van Waes; Z Chen
Journal:  Oncogene       Date:  2013-03-04       Impact factor: 9.867

View more
  10 in total

Review 1.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 2.  Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Authors:  Faiza Naz; Mengran Shi; Salvia Sajid; Zhao Yang; Changyuan Yu
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 3.  Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.

Authors:  Marika Quadri; Alessandra Marconi; Simran K Sandhu; Alexi Kiss; Tatiana Efimova; Elisabetta Palazzo
Journal:  Front Med (Lausanne)       Date:  2022-05-09

4.  Genomic landscape and clonal architecture of mouse oral squamous cell carcinomas dictate tumour ecology.

Authors:  Inês Sequeira; Mamunur Rashid; Inês M Tomás; Marc J Williams; Trevor A Graham; David J Adams; Alessandra Vigilante; Fiona M Watt
Journal:  Nat Commun       Date:  2020-11-09       Impact factor: 14.919

Review 5.  Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.

Authors:  Stephenie Droll; Xiaomin Bao
Journal:  Cell Physiol Biochem       Date:  2021-09-22

Review 6.  Pleiotropic effects of DCLK1 in cancer and cancer stem cells.

Authors:  Dibyashree Chhetri; Srinivasan Vengadassalapathy; Santhosh Venkadassalapathy; Varadharaju Balachandran; Vidhya Rekha Umapathy; Vishnu Priya Veeraraghavan; Selvaraj Jayaraman; Shankargouda Patil; Ashok Iyaswamy; Kanagaraj Palaniyandi; Dhanavathy Gnanasampanthapandian
Journal:  Front Mol Biosci       Date:  2022-09-26

Review 7.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

Review 8.  Cancer Stem Cells, Quo Vadis? The Notch Signaling Pathway in Tumor Initiation and Progression.

Authors:  Christian T Meisel; Cristina Porcheri; Thimios A Mitsiadis
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600

Review 9.  Pterygium-The Good, the Bad, and the Ugly.

Authors:  Sara I Van Acker; Bert Van den Bogerd; Michel Haagdorens; Vasiliki Siozopoulou; Sorcha Ní Dhubhghaill; Isabel Pintelon; Carina Koppen
Journal:  Cells       Date:  2021-06-22       Impact factor: 6.600

Review 10.  Notch signaling pathway: architecture, disease, and therapeutics.

Authors:  Binghan Zhou; Wanling Lin; Yaling Long; Yunkai Yang; Huan Zhang; Kongming Wu; Qian Chu
Journal:  Signal Transduct Target Ther       Date:  2022-03-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.